CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 119 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,240,349 | +47.1% | 83,189 | +8.1% | 0.00% | – |
| Q2 2023 | $843,244 | +164.3% | 76,957 | +110.4% | 0.00% | – |
| Q1 2023 | $319,022 | +1287.1% | 36,585 | +401.0% | 0.00% | – |
| Q1 2022 | $23,000 | +21.1% | 7,302 | +31.4% | 0.00% | – |
| Q4 2021 | $19,000 | -5.0% | 5,558 | 0.0% | 0.00% | – |
| Q3 2021 | $20,000 | -16.7% | 5,558 | 0.0% | 0.00% | – |
| Q2 2021 | $24,000 | -44.2% | 5,558 | -41.2% | 0.00% | – |
| Q1 2021 | $43,000 | -20.4% | 9,457 | 0.0% | 0.00% | – |
| Q4 2020 | $54,000 | +22.7% | 9,457 | +54.9% | 0.00% | – |
| Q3 2020 | $44,000 | +46.7% | 6,106 | -28.2% | 0.00% | – |
| Q2 2020 | $30,000 | +50.0% | 8,503 | -36.7% | 0.00% | – |
| Q1 2020 | $20,000 | -37.5% | 13,434 | -18.1% | 0.00% | – |
| Q4 2019 | $32,000 | -54.9% | 16,404 | +19.3% | 0.00% | – |
| Q3 2019 | $71,000 | -27.6% | 13,746 | 0.0% | 0.00% | – |
| Q2 2019 | $98,000 | -30.0% | 13,746 | +29.7% | 0.00% | – |
| Q1 2019 | $140,000 | +79.5% | 10,595 | +6.6% | 0.00% | – |
| Q4 2018 | $78,000 | -29.1% | 9,941 | 0.0% | 0.00% | – |
| Q3 2018 | $110,000 | -17.9% | 9,941 | 0.0% | 0.00% | – |
| Q2 2018 | $134,000 | – | 9,941 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |